Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
5.17
-0.16 (-2.91%)
Aug 14, 2025, 11:31 AM - Market open
Entrada Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 72.48 | 101.21 | 67.6 | 45.16 | 291.06 | 39.05 | Upgrade
|
| Short-Term Investments | 281.53 | 318.79 | 284.37 | 143.56 | - | - | Upgrade
|
| Cash & Short-Term Investments | 354.01 | 420 | 351.97 | 188.71 | 291.06 | 39.05 | Upgrade
|
| Cash Growth | -24.64% | 19.33% | 86.51% | -35.16% | 645.46% | 131.80% | Upgrade
|
| Accounts Receivable | 1.18 | 3.68 | 5.88 | - | - | - | Upgrade
|
| Other Receivables | 2.2 | 1.8 | 1.7 | 0.6 | - | - | Upgrade
|
| Receivables | 3.38 | 5.48 | 7.58 | 0.6 | - | - | Upgrade
|
| Prepaid Expenses | 11.75 | 14.16 | 10.22 | 20.56 | 7.64 | 0.9 | Upgrade
|
| Other Current Assets | - | 0.4 | - | - | - | - | Upgrade
|
| Total Current Assets | 369.15 | 440.04 | 369.77 | 209.88 | 298.7 | 39.95 | Upgrade
|
| Property, Plant & Equipment | 75.49 | 82.05 | 92.68 | 33.02 | 6.26 | 3.04 | Upgrade
|
| Other Long-Term Assets | 4.15 | 4.23 | 6.74 | 9.16 | 0.87 | 0.54 | Upgrade
|
| Total Assets | 448.78 | 526.32 | 469.19 | 252.06 | 305.83 | 43.53 | Upgrade
|
| Accounts Payable | 1.86 | 4.26 | 3.28 | 5.99 | 0.71 | 1.6 | Upgrade
|
| Accrued Expenses | 11.32 | 12.3 | 10.32 | 7.15 | 5.53 | 1.64 | Upgrade
|
| Current Portion of Leases | 5.46 | 7.56 | 7.91 | 8.41 | - | - | Upgrade
|
| Current Income Taxes Payable | - | 0.67 | 4.02 | - | - | - | Upgrade
|
| Current Unearned Revenue | 0.69 | 13.65 | 132.26 | - | - | - | Upgrade
|
| Other Current Liabilities | 0.47 | 1.04 | 1 | 0.43 | 0.49 | 0.12 | Upgrade
|
| Total Current Liabilities | 19.8 | 39.48 | 158.8 | 21.97 | 6.72 | 3.36 | Upgrade
|
| Long-Term Leases | 49.28 | 51.65 | 60.32 | 17.53 | - | - | Upgrade
|
| Long-Term Unearned Revenue | 0.19 | 6.51 | 7.72 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 0.4 | - | Upgrade
|
| Total Liabilities | 69.28 | 97.64 | 226.83 | 39.5 | 7.12 | 3.36 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | - | Upgrade
|
| Additional Paid-In Capital | 568.9 | 558.06 | 437.13 | 402.89 | 392.38 | 1.02 | Upgrade
|
| Retained Earnings | -189.8 | -129.34 | -194.97 | -188.29 | -93.67 | -42.51 | Upgrade
|
| Comprehensive Income & Other | 0.4 | -0.04 | 0.2 | -2.06 | - | - | Upgrade
|
| Total Common Equity | 379.51 | 428.68 | 242.36 | 212.55 | 298.72 | -41.49 | Upgrade
|
| Shareholders' Equity | 379.51 | 428.68 | 242.36 | 212.55 | 298.72 | 40.17 | Upgrade
|
| Total Liabilities & Equity | 448.78 | 526.32 | 469.19 | 252.06 | 305.83 | 43.53 | Upgrade
|
| Total Debt | 54.74 | 59.21 | 68.23 | 25.94 | - | - | Upgrade
|
| Net Cash (Debt) | 299.27 | 360.79 | 283.74 | 162.78 | 291.06 | 39.05 | Upgrade
|
| Net Cash Growth | -26.16% | 27.16% | 74.31% | -44.08% | 645.46% | 131.80% | Upgrade
|
| Net Cash Per Share | 7.30 | 9.25 | 8.59 | 5.20 | 46.44 | 35.33 | Upgrade
|
| Filing Date Shares Outstanding | 35.55 | 35.63 | 32.33 | 33.08 | 31.25 | 1.41 | Upgrade
|
| Total Common Shares Outstanding | 35.55 | 35.61 | 32.17 | 31.39 | 31.22 | 1.24 | Upgrade
|
| Working Capital | 349.34 | 400.56 | 210.98 | 187.9 | 291.98 | 36.59 | Upgrade
|
| Book Value Per Share | 10.68 | 12.04 | 7.53 | 6.77 | 9.57 | -33.35 | Upgrade
|
| Tangible Book Value | 379.51 | 428.68 | 242.36 | 212.55 | 298.72 | -41.49 | Upgrade
|
| Tangible Book Value Per Share | 10.68 | 12.04 | 7.53 | 6.77 | 9.57 | -33.35 | Upgrade
|
| Machinery | 19.1 | 18.42 | 15.26 | 8.54 | 6.12 | 2.16 | Upgrade
|
| Construction In Progress | - | - | - | 0.58 | - | - | Upgrade
|
| Leasehold Improvements | 2.05 | 1.93 | 1.86 | 1.86 | 1.56 | 1.25 | Upgrade
|
Updated Aug 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.